SCID

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Jasper Therapeutics
Jasper TherapeuticsREDWOOD CITY, CA
1 program
1
Humanized anti-CD117 Monoclonal AntibodyPhase 1/21 trial
Active Trials
NCT02963064TerminatedEst. Jul 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Jasper TherapeuticsHumanized anti-CD117 Monoclonal Antibody

Clinical Trials (1)

NCT02963064Jasper TherapeuticsHumanized anti-CD117 Monoclonal Antibody

JSP191 Antibody Targeting Conditioning in SCID Patients

Start: Mar 2017Est. completion: Jul 2025
Phase 1/2Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space